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Objective: MRI-detected structural features are associated with increased risk of radiographic osteoarthritis 
(ROA).  Specific mitochondrial DNA (mtDNA) haplogroups have been associated with incident ROA. Our objective 
was to compare the presence of MRI-detected structural features across mtDNA haplogroups among knees that 
developed incident ROA. 
Design: Knees from the Osteoarthritis Initiative that developed incident ROA during 48 months follow-up were 
identified from Caucasian participants. mtDNA haplogroups were assigned based on a single base extension 
assay. MRIs were obtained annually between baseline and 4-year follow-up and scored using the MRI 
Osteoarthritis Knee Score (MOAKS). The association between mtDNA haplogroups and MRI-detected structural 
features was estimated using log-binomial regression. Participants who carried haplogroup H served as the 
reference group. 
Results: The sample included 255 participants contributing 277 knees that developed ROA. Haplogroups 
included H (116, 45%), J (17, 7%), T (26, 10%), Uk (61, 24%), and the remaining less common haplogroups 
(“others”) (35, 14%). Knees of participants with haplogroup J had significantly lower risk of medium/large BMLs 
in the medial compartment [3.2%, RR=0.17; 95%CI: 0.05, 0.64;p=0.009] compared to knees of participants who 
carried haplogroup H [16.3%], as did knees from participants within the “others” group [2.8%, RR=0.20; 95%CI: 
0.08, 0.55;p=0.002], over the four year follow-up period.  
Conclusions: mtDNA haplogroup J was associated with lower risk of BMLs in the medial compartment among 
knees that developed ROA.  Our results offer a potential hypothesis to explain the mechanism underlying the 
previously reported protective association between haplogroup J and ROA. 
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Knee Osteoarthritis (OA) is a chronic condition that affects an estimated 250 million adults worldwide1.The initial 
steps of disease manifestation involve molecular derangements followed by structural tissue damage that 
involves cartilage degradation, as well as synovial inflammation, subchondral sclerosis and damage to other joint 
structures such as menisci and ligaments, eventually resulting in loss of articular function and pain2.Despite high 
prevalence, available therapies to treat OA are limited in terms of efficacy and safety, and existing treatments 
are only palliative. Prevention efforts and development of disease-modifying treatments require identification of 
modifiable targets, ideally with insights underlying the mechanisms involved.  
 
Multi-feature assessment of joint structure in knee OA has been accomplished through the use of semi-
quantitative scoring of magnetic resonance imaging (MRI)3. Articular tissues commonly assessed include 
cartilage damage, subchondral bone marrow lesions (BMLs) and cysts, osteophytes, bone attrition, 
synovitis/effusion, periarticular cysts/bursitis, anterior and posterior cruciate ligaments, the collateral ligaments, 
the menisci, and intra-articular loose bodies.   
 
Mitochondria contain their own genetic material, mitochondrial DNA (mtDNA), which codes for 13 essential 
peptides of the mitochondrial respiratory chain, as well as for 22 transferent RNAs (tRNAs) and 2 ribosomal 
RNAs (rRNAs). As a consequence of the high mutation rate of mtDNA, there are distinct haplogroups, defined by 
the presence of a particular set of single nucleotide polymorphisms (SNPs) in the mtDNA sequence. These 
mtDNA haplogroups are the result of maternally inherited mutations in the mtDNA acquired throughout human 
history and shaped by climate selection when humans migrated into colder climates4. Specific polymorphisms 
that are characteristic of the different mitochondrial haplogroups influence the behavior of the mitochondria 
and interact with the nuclear genome modulating critical processes such as complement activation, 
inflammation or apoptosis5, and therefore they have been associated with degenerative disorders6, metabolic 
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alterations7 and longevity8. The role of mitochondria in the pathogenesis of OA has been previously described9, 
and mtDNA haplogroups have been associated with the prevalence10, incidence, and progression of radiographic 
knee OA (ROA) in different cohorts worldwide11-14. 
 
Knee structural pathologies have been associated with the development of ROA15, radiographic progression16 
and incident knee pain17. Whether genetic variability influences the underlying pathology of OA is largely 
unknown, however. Notably, mtDNA haplogroup J has been associated with a lower rate of incident ROA14. Our 
objective was to compare the presence of MRI-detected structural features across mtDNA haplogroups among 




The Osteoarthritis Initiative (OAI) is a multi-center, longitudinal, prospective observational study of knee 
osteoarthritis. Study overview, objectives, protocol, and data are available online (https://oai.epi-
ucsf.org/datarelease/About.asp).  Briefly, 4,796 men and women with or at risk for knee osteoarthritis aged 45-
79 enrolled between February 2004 and May 2006 from the following sites: Ohio State University (Columbus, 
OH), University of Maryland School of Medicine and Johns Hopkins University School of Medicine (Baltimore, 
MD), University of Pittsburgh School of Medicine (Pittsburgh, PA), Brown University School of Medicine and 
Memorial Hospital of Rhode Island (Pawtucket, RI).  The study was approved by the Institutional Review Board 
(IRB) of the OAI Coordinating Center at the University of California, San Francisco and the IRBs of each site.   
 
Knees that developed incident ROA within four years of OAI baseline were selected for annual MRI readings in a 
substudy, Pivotal Osteoarthritis Initiative MRI Analyses (POMA), including 355 knees from 323 participants15.  
Briefly, annual bilateral posteroanterior fixed-flexion weight-bearing radiographic views were obtained using a 
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SynaFlexerTM frame (Synarc, San Francisco, CA, USA) according to standardized procedures (https://oai.epi-
ucsf.org/datarelease/operationsManuals/RadiographicManual.pdf). Radiographs were centrally read and scored 
with Kellgren-Lawrence (KL) grades to ascertain the development of incident ROA (i.e., KL grade ≥2)18. 
 
Because our study aims to compare the presence of MRI-detected structural features across European mtDNA 
haplogroups, we restricted the POMA sample to self-identified Caucasian participants, to avoid confounding by 
population stratification. The available sample for analysis included 255 Caucasian participants contributing 277 
knees, with an average of 3.9 annual MRIs (4% with 2 MRIs; 35% with 3 MRIs; 27% with 4; 34% with 5 MRIs). 
 
Mitochondrial DNA haplogroup assignment 
The most common Caucasian mtDNA haplogroups were assigned to participants using a previously described 
assay10. Briefly, a multiplex polymerase chain reaction was performed to amplify the six mtDNA fragments that 
contain the diagnostic SNPs that enable the identification of the most common Caucasian mtDNA haplogroups. 
Resulting PCR fragments were then purified with ExoSap-IT (ThermoFisher Scientific, Waltham, MA, United 
States) and analyzed by the Single Base Extension (SBE) assay using the SNaPshot multiplex Kit (ThermoFisher 
Scientific, Waltham, MA, United States). Once purified with SAP (ThermoFisher Scientific, Waltham, MA, United 
States), resulting products were loaded into an ABI 3130XL genetic analyzer (ThermoFisher Scientific, Waltham, 
MA, United States) and informative SNPs were visualized with GeneMapper software v5.0. Haplogroups with a 
frequency below 5% were pooled into the “Others” group. 
Knee MRI Acquisition and Assessment 
Annual MRIs were obtained on identical 3T systems (Siemens Trio, Erlangen, Germany) and acquired with a 
dedicated quadrature transmit/receive knee coil using a coronal intermediate-weighted 2-dimensional turbo 
spin-echo sequence, a sagittal 3-dimensional dual-echo steady-state sequence and coronal and axial 
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reformations, and a sagittal intermediate-weighted fat-suppressed turbo spin-echo sequence.  The complete 
pulse sequence protocol and sequence parameters have been described previously19. 
 
Outcomes 
MRI-detected structural features of knee OA were assessed by two expert readers with extensive experience in 
MRI assessment of OA (FWR, AG) using the MRI Osteoarthritis Knee Score (MOAKS), a semi-quantitative scoring 
instrument20. Outcomes of interest included damage thought to be of greatest clinical significance, including 
medium/large effusion-synovitis, moderate/severe Hoffa-synovitis, BMLs scored as ≥33% of the subregional 
volume (grade 2 and 3 , i.e. moderate and large BMLs), meniscal tear/maceration, and meniscal extrusions 
≥3mm. Cartilage damage was defined as loss ≥10% of the surface area and/or ≥10% full-thickness loss. 
 
Statistical Methods 
Baseline characteristics of the sample were summarized, including participant age, sex, body mass index (BMI), 
and self-reported history of knee injury or knee surgery. The proportion of each mtDNA haplogroup with the 
outcome of interest (MRI-detected structural damage) was estimated and compared using log-binomial 
regression to estimate relative risks (RR) and 95% confidence intervals (CI), and Poisson regression with robust 
variance as a planned alternative when the log-binomial model failed to converge21. Participants who carried 
haplogroup H served as the reference group for comparisons since haplogroup H is the most common in the 
Caucasian population. Generalized estimating equations were used to account for repeated annual MRI 
observations of knees between baseline and four-year follow-up, and potentially two knees contributed per 
participant. All estimates were reported unadjusted, as well as adjusted for age, sex, and BMI. BMLs, cartilage 
damage, meniscal damage, and extrusions were examined at the compartment level, as well as at the knee 





The sample of 255 Caucasian participants contributing knees that developed incident ROA within four years of 
baseline had a mean age of 61 years (sd 8.7), was predominately female (64%) and overweight (43%) or obese 
(36%).  Haplogroups included H (116, 45%), J (17, 7%), T (26, 10%), Uk (61, 24%), and less common (<5%) 
haplogroups (“others”) (35, 14%).  
 
Modest imbalances in baseline characteristics existed between haplogroups; participants carrying haplogroup T 
were older, while participants carrying haplogroup J were more frequently male than other groups, and less 
often obese (Table 1).  Since these characteristics have the potential to confound associations between mtDNA 
haplogroup and MRI-detected structural features in our sample, we interpreted results from the adjusted 
analyses. 
 
Knees of participants with haplogroup J had significantly lower risk of large BMLs in the medial compartment 
[3.2%, RR=0.17; 95%CI: 0.05, 0.64; p=0.009] compared to knees of participants who carried haplogroup H 
[16.3%], as did knees from participants within the “others” group [2.8%, RR=0.20; 95%CI: 0.08, 0.55; p=0.002]. 
While 4.7% of haplogroup H carriers had large BMLs detected in the lateral compartment, haplogroup J carriers 
had none, potentially suggesting a protective effect of haplogroup J for tibiofemoral BMLs overall [3.2% in J vs 
18.8% in H; RR=0.15; 95%CI: 0.04, 0.57; p=0.005]. No evidence of an association between haplogroups and BMLs 
in the patello-femoral joint (PFJ) was observed (Table 2). 
 
Hoffa´s synovitis (moderate/severe) and effusion-synovitis (medium/large) were less common among 
participants carrying haplogroup J compared to H, though the differences were not statistically significant [1.7% 
vs 10.1%, RR=0.16; 95%CI: 0.02, 1.16; p=0.070 and 9.5% vs 17.3%, RR=0.55; 95%CI: 0.20, 1.52; p=0.248, 




Higher risk of meniscal tear/maceration in the lateral compartment was seen among participants carrying 
haplogroups J [31.8%, RR=3.35; 95%CI: 1.30, 8.61; p=0.012], T [28.3%, RR=3.06; 95%CI: 1.47, 6.39; p=0.003], and 
Uk [25.0%, RR=2.73; 95%CI: 1.45, 5.13; p=0.002], compared to haplogroup H [9.1%].  Similarly, carriers of 
haplogroup T experienced a higher risk of meniscal extrusion ≥3mm in the lateral compartment [11.5%, 
RR=11.7; 95%CI: 2.90, 47.22; p=0.001], compared to haplogroup H [0.8%]. No remarkable effect sizes or 
significant differences in cartilage damage were observed between haplogroups (Table 3). 
 
DISCUSSION 
In our longitudinal observational study of participants who developed radiographic incident knee OA, those who 
carried mtDNA haplogroup J were significantly less likely to have large tibiofemoral BMLs compared to 
participants who carried the more common haplogroup H.  
 
Severe early changes in different articular features, especially BMLs and meniscal pathology, have been 
associated with symptomatic progression and radiographic worsening over a 24-month period22, including 
increased risk of joint replacement and increased cartilage loss23. Specifically, BMLs have emerged as a central 
component of a wide variety of inflammatory and non-inflammatory rheumatologic conditions, and therefore 
they are not only potential sources of pain, but may also reflect disease activity24. BMLs have been consistently 
identified by MRI in patients with knee OA25-27 related to mechanical loading, as well as increased subchondral 
stress. BMLs are characterized by high bone turnover as well as an increased vascularization induced by 
angiogenic factors and pro-inflammatory cytokines, which could explain the elevated bone marker levels in 





Participants harboring the haplogroup J had a lower rate of large BMLs when compared with participants with 
haplogroup H. We hypothesize that both metabolic activity and inflammation that takes place in BMLs29 could 
be behind this association. 
 
Haplogroups J and H are substantially different with respect to nucleotide composition: haplogroup J comprises 
a set of uncoupling mitochondrial polymorphisms, preferentially non-synonymous, acquired during evolutionary 
history4, 30, while haplogroup H has higher levels of conserved amino acids4. Thus, these haplogroups are 
biochemically different in terms of oxidative phosphorylation system (OXPHOS) coupling efficiency, adenosine 
triphosphate (ATP) levels and reactive oxygen species (ROS) production31, 32, leading to different expression 
patterns of genes affecting several signalling pathways such as complement, inflammation or apoptosis5, 33. 
Further, cells harboring haplogroup J show lower ATP levels accompanied by decreased ROS production, while 
haplogroup H associates with higher ATP levels, increased ROS production and lower ability to cope with 
oxidative stress14, 34, 35. These characteristics make haplogroup J less efficient and metabolically active compared 
to H31, 35, however, haplogroup J also shows a decreased expression of genes affecting inflammation and 
apoptosis5. 
 
Metabolic differences between haplogroups H and J have additional consequences. Mitochondria-derived ROS 
also leads to an upregulation of metalloproteinases (MMPs)36, 37, as well as an overproduction of pro-
inflammatory cytokines38. Thus, MMP-13 is highly expressed in subchondral bone affected by BMLs29, and 
increased levels of IL-6 and C-reactive protein have been detected in the serum of patients with large-BMLs39, 40. 
In addition, knee effusion-synovitis has been positively associated with BMLs41. We found that Hoffa’s synovitis 
and effusion-synovitis were less common in participants with the haplogroup J, although not statistically 
significant. Interestingly, mtDNA haplogroups have been associated with serum levels of type-2 collagen 
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biomarkers and MMPs, where those participants with haplogroup J had lower serum levels of catabolic type-2 
collagen biomarkers and MMP-13 than those harboring the haplogroup H42, 43. 
 
Fernández-Moreno et al, in a meta-analysis of mtDNA haplogroups in 3214 subjects from OAI and CHECK 
cohorts, concluded that participants who carried haplogroup J had a lower risk of developing incident ROA over 
96 months of follow-up [ref 14]. Our study was restricted to OAI participants who developed incident ROA, and 
evaluated the association of mtDNA haplogroups with MRI-detected structural abnormalities not visible on 
radiographs, in the years leading up to ROA. We found a lower frequency of large BMLs, potentially as a 
consequence of differences in genetically-driven metabolic activity and inflammation at the cellular level. Soto-
Hermida et al reported that among OAI participants with prevalent disease at baseline (i.e., the progression 
subcohort of the OAI, defined as having frequent knee symptoms and ROA at baseline) carriers of haplogroup T 
had a lower rate of cartilage deterioration [ref 44]. In our sample of early OA knees, there was no evidence of an 
association between mtDNA haplogroups and cartilage damage. This is not entirely surprising given that incident 
ROA is defined by radiographic detection of an osteophyte, often prior to evidence of joint space narrowing, 
while disease progression following ROA is characterized by more profound cartilage loss. Our findings, together 
with the earlier studies [references 14 and 44], highlight the relevance of the mitochondrial genome in the 
development and progression of knee OA, and offer a hypothesis for the potential mechanism underlying the 
protective effect of haplogroup J in the development of incident radiographic knee OA and haplogroup T in the 
progression of prevalent knee OA.  
 
Significant associations between mtDNA haplogroups and meniscal damage and extrusions were also found. 
Meniscal tears are categorized as traumatic or non-traumatic (degenerative). Traumatic tears are usually caused 
by a serious injury, often during sports participation; degenerative tears are more common in the medial 
compartment and often accompanied by knee OA, with increased prevalence as joint space narrowing becomes 
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more severe45. Participants with haplogroup H had a significantly lower prevalence of meniscal tears in the 
lateral compartment. We do not have a definitive explanation for this finding, though we speculate that since 
these differences were detected in the lateral compartment, which is less commonly associated with 
degenerative tears, the association could be related to traumatic episodes or even to knee alignment.  
 
Our findings should be interpreted in context of the limitations. Our study had a limited sample of 255 Caucasian 
participants contributing 277 knees, and we examined multiple outcomes, yet this is a well-characterized cohort 
of participants, evaluated by objective methods at annual visits with detailed imaging assessments of OA 
pathology. In addition, this work examined the forms of joint damage with the greatest potential clinical 
relevance. Due to the multiple comparisons, the study findings could be considered hypothesis-generating, and 
replication should be attempted in an independent sample. 
 
In summary, participants carrying the mtDNA haplogroup J had a lower risk of large BMLs in the tibio-femoral 
medial compartment compared to participants carrying the common haplogroup H among knees from the OAI 
that developed ROA during 48 months follow-up.  Our results offer a potential hypothesis to explain the 
mechanism underlying the protective effect of haplogroup J for ROA that has been previously reported14.  
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Table 1. Baseline characteristics by mtDNA haplogroup 
 Haplotype 
  H J T  Uk Others* All 
 Participant-level 
 n=116 n=17 n=26 n=61 n=35 n=255 
Age, years, mean(sd) 60.7 (9.0) 60.4 (7.6) 63.6 (8.4) 62.2 (8.3) 59.9 (9.1) 61.3 (8.7) 
Sex, Male (%) 45 (38.8) 8 (47.1) 8 (30.8) 24 (39.3) 7 (20.0) 92 (36.1) 
BMI (Kg/m2), mean(sd) 28.7 (4.6) 27.1 (3.8) 28.3 (4.8) 28.5 (4.3) 29.2 (3.9) 28.6 (4.4) 
    Normal (18.5-24.9 kg) (%) 23 (19.8) 7 (41.2) 6 (23.1) 13 (21.3) 6 (17.1) 55 (21.6) 
    Overweight (25-29.9 kg) (%) 54 (46.6) 6 (35.3) 11 (42.3) 25 (41.0) 13 (37.1) 109 (42.7) 
    Obese (≥30 kg) (%) 39 (33.6) 4 (23.5) 9 (34.6) 23 (37.7) 16 (45.7) 91 (35.7) 
 Knee-level 
 n=126 n=17 n=29 n=67 n=38 n=277 
History of knee injury (%) 44 (35.2) 6 (35.3) 3 (10.3) 14 (21.5) 5 (13.2) 72 (26.3) 
History of knee surgery or arthroscopy 
(%) 
10 (8.0) 2 (11.8) 0 (0.0) 4 (6.0) 0 (0.0) 16 (5.8) 
Abbreviations: BMI, Body Mass Index; sd, standard deviation 




Table 2. Mitochondrial DNA haplogroups and association with synovitis and bone marrow lesions 
Haplogroup MRI-detected Structural Features 
 Feature Presenta (%) RR  (95%CI) P-value     Adjustedb RR    (95%CI)    P-value 
Effusion-Synovitis and Hoffa-synovitis 
 Hoffa’s synovitis, Moderate/Severe      
     H  49 (10.1) 1.00 (reference)   1.00 (reference)  
     J 1 (1.7) 0.16 (0.02, 1.19) 0.074  0.16 (0.02, 1.16) 0.070 
     T  11 (9.7) 0.96 (0.37, 2.51) 0.939  0.96 (0.37, 2.52) 0.938 
     Uk 26 (9.4) 0.93 (0.46, 1.90) 0.847  0.91 (0.45, 1.85) 0.800 
     Others 5 (3.5) 0.34 (0.10, 1.15) 0.083  0.40 (0.12, 1.36) 0.142 
 Effusion synovitis, Medium/Large      
     H  84 (17.3) 1.00 (reference)   1.00 (reference)  
     J 6 (9.5) 0.55 (0.20, 1.51) 0.246  0.55 (0.20, 1.52) 0.248 
     T  24 (21.2) 1.23 (0.69, 2.17) 0.485  1.25 (0.70, 2.23) 0.443 
     Uk 36 (13.0) 0.75 (0.47, 1.22) 0.246  0.75 (0.46, 1.22) 0.248 
     Others 15 (10.3) 0.60 (0.29, 1.22) 0.156  0.61 (0.30, 1.24) 0.168 
 Hoffa’s synovitis (Moderate/Severe) or Effusion-synovitis (Medium/Large)  
     H  113 (23.3) 1.00 (reference)   1.00 (reference)  
     J 7 (11.1) 0.48 (0.20, 1.15) 0.099  0.46 (0.19, 1.12) 0.086 
     T  32 (28.3) 1.22 (0.75, 1.97) 0.428  1.25 (0.77, 2.02) 0.373 
     Uk 53 (19.2) 0.82 (0.55, 1.25) 0.359  0.82 (0.54, 1.24) 0.349 
     Others 20 (13.8) 0.59 (0.33, 1.06) 0.079  0.62 (0.35, 1.11) 0.111 
Bone Marrow Lesions (≥33% subregional volume) 
 Whole knee        
     H  208 (42.9) 1.00 (reference)   1.00 (reference)  
     J 23 (36.5) 0.85 (0.51, 1.43) 0.540  0.80 (0.46, 1.38) 0.424 
     T  49 (43.4) 1.01 (0.67, 1.53) 0.958  0.99 (0.66, 1.48) 0.946 
     Uk 100 (36.2) 0.84 (0.62, 1.15) 0.282  0.83 (0.61, 1.12) 0.219 
     Others 52 (35.9) 0.84 (0.57, 1.23) 0.359  0.87 (0.59, 1.28) 0.475 
 Whole knee (no PFJ)        
     H  91 (18.8) 1.00 (reference)   1.00 (reference)  
     J 2 (3.2) 0.17 (0.05, 0.64) 0.009  0.15 (0.04, 0.57) 0.005 
     T  17 (15.0) 0.80 (0.35, 1.82) 0.597  0.80 (0.36, 1.74) 0.568 
     Uk 45 (16.3) 0.87 (0.56, 1.36) 0.539  0.83 (0.54, 1.29) 0.417 
     Others 8 (5.5) 0.29 (0.14, 0.63) 0.002  0.34 (0.16, 0.73) 0.006 
 Medial compartment        
     H  79 (16.3) 1.00 (reference)   1.00 (reference)  
     J 2 (3.2) 0.19 (0.05, 0.74) 0.016  0.17 (0.05, 0.64) 0.009 
     T  10 (8.9) 0.54 (0.19, 1.59) 0.266  0.55 (0.19, 1.56) 0.260 
     Uk 29 (10.5) 0.65 (0.37, 1.12) 0.118  0.62 (0.36, 1.07) 0.086 
     Others 4 (2.8) 0.17 (0.06, 0.46) 0.001  0.20 (0.08, 0.55) 0.002 
 Lateral compartment        
16 
 
     H  23 (4.7) 1.00 (reference)   1.00 (reference)  
     J 0 (0.0) … … …  … … … 
     T  9 (8.0) 1.68 (0.53, 5.32) 0.378  1.64 (0.57, 4.74) 0.358 
     Uk 18 (6.5) 1.38 (0.56, 3.37) 0.487  1.34 (0.56, 3.23) 0.516 
     Others 5 (3.5) 0.73 (0.23, 2.37) 0.603  0.80 (0.23, 2.80) 0.730 
 PFJ        
     H  140 (28.9) 1.00 (reference)   1.00 (reference)  
     J 22 (34.9) 1.21 (0.67, 2.16) 0.527  1.21 (0.67, 2.19) 0.519 
     T  44 (38.9) 1.35 (0.83, 2.19) 0.230  1.30 (0.80, 2.10) 0.284 
     Uk 76 (27.5) 0.95 (0.62, 1.45) 0.819  0.93 (0.61, 1.42) 0.733 
     Others 46 (31.7) 1.10 (0.68, 1.76) 0.703  1.13 (0.70, 1.80) 0.622 
Abbreviations: PFJ, Patello-Femoral Joint; RR, Relative Risk; CI, Confidence Interval 
aNumber of MRIs with feature present with at least moderate/medium severity/size, with repeated annual MRIs 
for each knee. 




Table 3. Mitochondrial DNA haplogroups and association with cartilage damage and meniscal damage 
Haplogroup MRI-detected Structural Features 
 Feature Presenta (%) RR  (95%CI) P-value     Adjustedb RR    (95%CI)    P-value 
 
Cartilage Damage 
 Whole knee        
     H  446 (92.0) 1.00 (reference)   1.00 (reference)  
     J 55 (87.3) 0.95 (0.80, 1.13) 0.551  0.97 (0.82, 1.13) 0.681 
     T  99 (87.6) 0.95 (0.83, 1.09) 0.489  0.93 (0.82, 1.06) 0.302 
     Uk 233 (84.4) 0.92 (0.82, 1.02) 0.119  0.91 (0.82, 1.01) 0.070 
     Others 128 (88.3) 0.96 (0.87, 1.06) 0.426  0.97 (0.88, 1.06) 0.468 
 Whole knee (no PFJ)        
     H  305 (62.9) 1.00 (reference)   1.00 (reference)  
     J 42 (66.7) 1.06 (0.77, 1.46) 0.719  1.05 (0.77, 1.42) 0.772 
     T  72 (63.7) 1.01 (0.79, 1.30) 0.917  0.95 (0.73, 1.23) 0.695 
     Uk 159 (57.6) 0.92 (0.74, 1.13) 0.421  0.90 (0.74, 1.09) 0.290 
     Others 81 (55.9) 0.89 (0.68, 1.16) 0.380  0.92 (0.71, 1.20) 0.532 
 Medial compartment        
     H  229 (47.2) 1.00 (reference)   1.00 (reference)  
     J 20 (31.8) 0.67 (0.36, 1.24) 0.206  0.72 (0.42, 1.25) 0.246 
     T  44 (38.9) 0.82 (0.55, 1.24) 0.351  0.81 (0.55, 1.20) 0.299 
     Uk 108 (39.1) 0.83 (0.61, 1.12) 0.221  0.83 (0.62, 1.10) 0.193 
     Others 61 (42.1) 0.89 (0.62, 1.29) 0.542  0.95 (0.64, 1.41) 0.792 
 Lateral compartment        
     H  159 (32.8) 1.00 (reference)   1.00 (reference)  
     J 28 (44.4) 1.36 (0.75, 2.46) 0.318  1.35 (0.74, 2.47) 0.325 
     T  38 (33.6) 1.03 (0.60, 1.75) 0.926  1.02 (0.61, 1.73) 0.933 
     Uk 100 (36.2) 1.11 (0.76, 1.62) 0.606  1.10 (0.75, 1.61) 0.622 
     Others 47 (32.4) 0.99 (0.61, 1.60) 0.963  1.03 (0.64, 1.67) 0.894 
 PFJ        
     H  366 (75.5) 1.00 (reference)   1.00 (reference)  
     J 49 (77.8) 1.03 (0.79, 1.34) 0.824  1.08 (0.85, 1.37) 0.543 
     T  90 (79.7) 1.06 (0.86, 1.30) 0.611  1.02 (0.83, 1.25) 0.855 
     Uk 206 (74.6) 0.99 (0.84, 1.17) 0.897  0.97 (0.82, 1.14) 0.728 
     Others 108 (74.5) 0.99 (0.79, 1.23) 0.906  0.98 (0.80, 1.20) 0.820 
Meniscus Tear/Maceration 
 Whole knee        
     H  263 (54.2) 1.00 (reference)   1.00 (reference)  
     J 44 (69.8) 1.29 (0.94, 1.77) 0.116  1.11 (0.77, 1.61) 0.566 
     T  61 (54.0) 1.00 (0.72, 1.38) 0.978  1.06 (0.82, 1.37) 0.661 
     Uk 181 (65.6) 1.21 (0.98, 1.49) 0.071  1.14 (0.94, 1.37) 0.187 
     Others 51 (35.2) 0.65 (0.43, 0.97) 0.034  0.70 (0.47, 1.03) 0.070 
 Medial compartment        
18 
 
     H  232 (47.8) 1.00 (reference)   1.00 (reference)  
     J 29 (46.0) 0.96 (0.57, 1.63) 0.886  0.85 (0.53, 1.37) 0.509 
     T  40 (35.4) 0.74 (0.47, 1.16) 0.186  0.86 (0.61, 1.21) 0.374 
     Uk 136 (49.3) 1.03 (0.78, 1.35) 0.832  0.97 (0.77, 1.23) 0.799 
     Others 41 (28.3) 0.59 (0.36, 0.97) 0.037  0.63 (0.38, 1.05) 0.075 
 Lateral compartment        
     H  44 (9.1) 1.00 (reference)   1.00 (reference)  
     J 20 (31.8) 3.50 (1.43, 8.54) 0.006  3.35 (1.30, 8.61) 0.012 
     T  32 (28.3) 3.12 (1.43, 6.82) 0.004  3.06 (1.47, 6.39) 0.003 
     Uk 69 (25.0) 2.76 (1.45, 5.24) 0.002  2.73 (1.45, 5.13) 0.002 
     Others 18 (12.4) 1.37 (0.53, 3.50) 0.513  1.51 (0.57, 3.96) 0.404 
Meniscus Extrusion (≥3mm) 
 Whole knee        
     H  95 (19.6) 1.00 (reference)   1.00 (reference)  
     J 11 (17.5) 0.89 (0.32, 2.50) 0.827  0.91 (0.32, 2.59) 0.866 
     T  34 (30.1) 1.54 (0.92, 2.57) 0.101  1.40 (0.83, 2.35) 0.203 
     Uk 50 (18.1) 0.92 (0.59, 1.46) 0.736  0.88 (0.57, 1.37) 0.569 
     Others 19 (13.1) 0.67 (0.34, 1.30) 0.234  0.69 (0.36, 1.32) 0.263 
 Medial compartment        
     H  91 (18.8) 1.00 (reference)   1.00 (reference)  
     J 8 (12.7) 0.68 (0.19, 2.38) 0.543  0.70 (0.20, 2.48) 0.583 
     T  21 (19.6) 0.99 (0.54, 1.81) 0.975  0.93 (0.51, 1.70) 0.824 
     Uk 42 (15.2) 0.81 (0.49, 1.35) 0.420  0.77 (0.47, 1.28) 0.315 
     Others 19 (13.1) 0.70 (0.36, 1.36) 0.292  0.73 (0.38, 1.43) 0.363 
 Lateral compartment        
     H  4 (0.8) 1.00 (reference)   1.00 (reference)  
     J 3 (4.8) 5.77 (0.60, 55.70) 0.130  6.22 (0.66, 58.83) 0.111 
     T  13 (11.5) 13.95 (3.04, 64.09) 0.001  11.70 (2.90, 47.22) 0.001 
     Uk 8 (2.9) 3.51 (0.77, 16.07) 0.105  3.34 (0.72, 15.39) 0.123 
     Others 0 (0.0) … … …   … … … 
Abbreviations: PFJ, Patello-Femoral Joint; RR, Relative Risk; CI, Confidence Interval 
aNumber of MRIs with feature present with at least moderate/medium severity/size, with repeated annual MRIs 
for each knee. 
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